Information Provided By:
Fly News Breaks for March 2, 2017
CELG, XLRN
Mar 2, 2017 | 05:56 EDT
Citi analyst Robyn Karnauskas upgraded Acceleron Pharma (XLRN) to Buy saying the recent weakness provides a good entry point. The stock reflects $1.5B in sales, but Luspatercept alone could be worth $2B-$4B, Karnauskas tells investors in a research note. She sees "several catalysts" over next three years and highlights the company's "robust" partnership with Celgene (CELG). Karnauskas lowered her price target for Acceleron shares to $36 from $40.
News For XLRN;CELG From the Last 2 Days
There are no results for your query XLRN;CELG